FindTrial
Sign In

Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518159-52-02
Enrollment
1
Registered
2025-01-27
Start date
Unknown
Completion date
2025-04-04
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypogonadotropic hypogonadism

Brief summary

Total testosterone serum levels

Interventions

DRUGLUTROPIN ALFA

Sponsors

Department Of Biomedical Metabolic And Neural Sciences
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Total testosterone serum levels—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026